Literature DB >> 17157622

Lung cancer.

Michelle S Ginsberg1, Ravinder K Grewal, Robert T Heelan.   

Abstract

Lung cancer is the most frequently occurring cancer in the world, and in the United States it is the second most common cancer diagnosed. Accurate staging by imaging can have a significant impact on appropriate treatment and surgical options. Familiarity with the different histologic subtypes of lung cancer and the typical and atypical appearances of lung cancer is vital. Radiologists serve a critical role in the diagnosis, staging, and follow-up of patients with lung cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17157622     DOI: 10.1016/j.rcl.2006.10.004

Source DB:  PubMed          Journal:  Radiol Clin North Am        ISSN: 0033-8389            Impact factor:   2.303


  24 in total

1.  Advanced squamous lung carcinoma in a patient experiencing long-term survival following repeated responses to gemcitabine and cisplatin chemotherapy: A case report.

Authors:  Min Yu; Shuang Zhang; Yanying Li; Zhenyu Ding; Feng Peng
Journal:  Oncol Lett       Date:  2015-04-02       Impact factor: 2.967

2.  Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation.

Authors:  Wenfeng Fang; Jianwei Zhang; Wenhua Liang; Yan Huang; Yue Yan; Xuan Wu; Zhihuang Hu; Yuxiang Ma; Hongyun Zhao; Yuanyuan Zhao; Yunpeng Yang; Cong Xue; Jing Zhang; Li Zhang
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

3.  A review of metabolism-associated biomarkers in lung cancer diagnosis and treatment.

Authors:  Sanaya Bamji-Stocke; Victor van Berkel; Donald M Miller; Hermann B Frieboes
Journal:  Metabolomics       Date:  2018-06-01       Impact factor: 4.290

4.  Lung cancers diagnosed at annual CT screening: volume doubling times.

Authors:  Claudia I Henschke; David F Yankelevitz; Rowena Yip; Anthony P Reeves; Ali Farooqi; Dongming Xu; James P Smith; Daniel M Libby; Mark W Pasmantier; Olli S Miettinen
Journal:  Radiology       Date:  2012-03-27       Impact factor: 11.105

5.  Serum M30 and M65 values in patients with advanced stage non-small-cell lung cancer compared with controls.

Authors:  Basak Oven Ustaalioglu; Ahmet Bilici; Serif Ercan; Asuman Orcun; Mesut Seker; Alper Ozkan; Recep Ustaalioglu; Mahmut Gumus
Journal:  Clin Transl Oncol       Date:  2012-05       Impact factor: 3.405

6.  Spectrum of LKB1, EGFR, and KRAS mutations in chinese lung adenocarcinomas.

Authors:  Bin Gao; Yihua Sun; Junhua Zhang; Yan Ren; Rong Fang; Xiangkun Han; Lei Shen; Xin-Yuan Liu; William Pao; Haiquan Chen; Hongbin Ji
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

7.  Lung cancer serum biomarker discovery using label-free liquid chromatography-tandem mass spectrometry.

Authors:  Xuemei Zeng; Brian L Hood; Ting Zhao; Thomas P Conrads; Mai Sun; Vanathi Gopalakrishnan; Himanshu Grover; Roger S Day; Joel L Weissfeld; David O Wilson; Jill M Siegfried; William L Bigbee
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

8.  Baseline and annual repeat rounds of screening: implications for optimal regimens of screening.

Authors:  Claudia I Henschke; Mary Salvatore; Matthew Cham; Charles A Powell; Larry DiFabrizio; Raja Flores; Andrew Kaufman; Corey Eber; Rowena Yip; David F Yankelevitz
Journal:  Eur Radiol       Date:  2017-10-05       Impact factor: 5.315

9.  Circulating microRNA-34 family low expression correlates with poor prognosis in patients with non-small cell lung cancer.

Authors:  Ke Zhao; Jing Cheng; Baojun Chen; Qi Liu; Di Xu; Yongjian Zhang
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

10.  Metastasis to the occipitocervical junction: A case report and review of the literature.

Authors:  Risheng Xu; Daniel M Sciubba; Ziya L Gokaslan; Ali Bydon
Journal:  Surg Neurol Int       Date:  2010-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.